SR One
Investment Details
Investor Type
Corporate VC
Asset Class Focus
Venture Capital
Stage Focus
Early Stage, Seed, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, China, India, France, Italy, Denmark, Switzerland, Spain, South Korea, Ireland, Netherlands, Sweden, Belgium, Norway, Finland
Industries Focus
- Healthcare
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Infectious Diseases
- Vaccines
- Immunology
- Genomics
- Rare Diseases
Investment Size:
5,000,000 to 50,000,000 USD
Investor Details Founded: 1985
SR One is a transatlantic biotechnology venture capital firm that partners with entrepreneurs and scientists to build elite biotechnology companies.
The firm focuses on early-stage investments in companies developing innovative medicines to address significant unmet medical needs.
Since its spin-out from GlaxoSmithKline in 2020, SR One has raised over $1 billion and invested in more than 20 companies, with offices in San Francisco, CA, and London, UK.
Requirements
- Innovative science with potential to impact medical care
- Strong underlying fundamentals
- Clearly defined development pathway
- Novel approaches to addressing diseases
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- CRISPR Therapeutics
- Principia Biopharma
- Turning Point Therapeutics
- Progyny
- Nkarta Therapeutics
- Avalyn Pharma
- Avenzo Therapeutics
- Mission Therapeutics
- Windward Bio
- Alumis
- ARS Pharmaceuticals
- Zenas BioPharma
Claim this Investor
Are you an official representative of SR One?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim